Unnati Pharmax

Demisone Tablet
Composition: Dexamethasone Tablets IP
International Trade Name: Decadron®

Demisone is a high-quality Dexamethasone Tablet, a bioequivalent formulation of the internationally recognized corticosteroid marketed under the brand name Decadron®. Manufactured in WHO-GMP certified facilities, Demisone Tablets are supplied by trusted pharmaceutical exporters from India to support global therapeutic programs across oncology, neurology, immunology, and critical care.

Dexamethasone is a potent synthetic glucocorticoid with strong anti-inflammatory, anti-allergic, and immunosuppressive properties. Demisone Tablets are widely used in the management of inflammatory and autoimmune disorders, cerebral edema, allergic reactions, adrenal insufficiency, and as an adjunct therapy in cancer care, including prevention of chemotherapy-induced nausea and management of brain tumor–associated edema.

Demisone Dexamethasone Tablets are manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, specialty clinics, oncology centers, government health programs, and international pharmaceutical distributors.

Temoside 250mg Capsule
Composition: Temozolomide Capsules 250mg IP
International Trade Name: Temodar®

Temoside 250 is a high-quality Temozolomide 250mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temoside Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temoside 250mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temoside 250mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Temoside 20mg Capsule
Composition: Temozolomide Capsules 20mg IP
International Trade Name: Temodar®

Temoside 20 is a high-quality Temozolomide 20mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temoside Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temoside 20mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temoside 20mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Temotero 20mg Capsule
Composition: Temozolomide Capsules 20mg IP
International Trade Name: Temodar®

Temotero 20 is a high-quality Temozolomide 20mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temotero Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temotero 20mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temotero 20mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Temoside 100mg Capsule
Composition: Temozolomide Capsules 100mg IP
International Trade Name: Temodar®

Temoside 100 is a high-quality Temozolomide 100mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temoside Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temoside 100mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temoside 100mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

TEMCAD 250mg Tablet
Composition: Temozolomide Tablets 250mg IP
International Trade Name: Temodar®

TEMCAD 250 is a high-quality Temozolomide 250mg Tablet, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, TEMCAD Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. TEMCAD 250mg Tablet is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

TEMCAD 250mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

TEMCAD 20mg Tablet
Composition: Temozolomide Tablets 20mg IP
International Trade Name: Temodar®

TEMCAD 20 is a high-quality Temozolomide 20mg Tablet, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, TEMCAD Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. TEMCAD 20mg Tablet is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

TEMCAD 20mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

TEMCAD 100mg Capsule
Composition: Temozolomide Capsules 100mg IP
International Trade Name: Temodar®

TEMCAD 100 is a high-quality Temozolomide 100mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, TEMCAD Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. TEMCAD 100mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

TEMCAD 100mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Glioz 20mg Capsule
Composition: Temozolomide Capsules 20mg IP
International Trade Name: Temodal® / Temodar®

Glioz 20 is a high-quality Temozolomide 20mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodal® / Temodar®. Manufactured in WHO-GMP certified facilities, Glioz Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that works by methylating DNA at the O6 and N7 positions of guanine, resulting in tumor cell death. Glioz 20mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Glioz 20mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Glioz 100mg Capsule
Composition: Temozolomide Capsules 100mg IP
International Trade Name: Temodar®

Glioz 100 is a high-quality Temozolomide 100mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Glioz Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts its cytotoxic action by methylating DNA at the O6 and N7 positions of guanine, resulting in tumor cell apoptosis. Glioz 100mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Glioz 100mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Temalieva 100mg Capsule
Composition: Temozolomide Capsules 100mg IP
International Trade Name: Temodar®

Temalieva 100 is a high-quality Temozolomide 100mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temalieva Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that works by methylating DNA at the O6 and N7 positions of guanine, leading to irreversible DNA damage and tumor cell apoptosis. Temalieva 100mg Capsule is primarily indicated for the treatment of newly diagnosed glioblastoma multiforme in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma and other malignant gliomas, as per approved treatment guidelines.

Temalieva 100mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Temzokey 100mg Capsule
Composition: Temozolomide Capsules 100mg IP
International Trade Name: Temodar®

Temzokey 100 is a high-quality Temozolomide 100mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temzokey Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts its cytotoxic effect by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temzokey 100mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temzokey 100mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Temzokey 250mg Capsule
Composition: Temozolomide Capsules 250mg IP
International Trade Name: Temodar®

Temzokey 250 is a high-quality Temozolomide 250mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temzokey Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts its cytotoxic effect by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temzokey 250mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temzokey 250mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Krabeva 400mg Injection
Composition: Bevacizumab 400mg/16mL (25mg/mL) Injection
International Trade Name: Avastin®

Krabeva 400 is a high-quality Bevacizumab 400mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Krabeva Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Krabeva 400mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Krabeva 400mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Cizumab 400mg Injection
Composition: Bevacizumab 400mg/16mL (25mg/mL) Injection
International Trade Name: Avastin®

Cizumab 400 is a high-quality Bevacizumab 400mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Cizumab Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Cizumab 400mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Cizumab 400mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Versavo 100mg Injection
Composition: Bevacizumab 100mg/4mL (25mg/mL) Injection
International Trade Name: Avastin®

Versavo 100 is a high-quality Bevacizumab 100mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Versavo Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Versavo 100mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Versavo 100mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Abevmy 400mg Injection
Composition: Bevacizumab 400mg/16mL (25mg/mL) Injection
International Trade Name: Avastin®

Abevmy 400 is a high-quality Bevacizumab 400mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Abevmy Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Abevmy 400mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Abevmy 400mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dexona 0.5mg Tablet
Composition: Dexamethasone Tablets 0.5mg
International Trade Name: Decadron®

Dexona 0.5 is a high-quality Dexamethasone 0.5mg Tablet, a bioequivalent formulation of the internationally recognized corticosteroid marketed under the brand name Decadron®. Manufactured in WHO-GMP certified facilities, Dexona Tablets are supplied by trusted pharmaceutical exporters from India to support global therapeutic programs across anti-inflammatory, immunosuppressive, and oncology supportive care applications.

Dexamethasone is a potent synthetic glucocorticoid that exhibits anti-inflammatory, immunosuppressive, and anti-allergic properties. Dexona 0.5mg Tablet is primarily indicated for the treatment of inflammatory and autoimmune disorders, allergic reactions, cerebral edema, and as an adjunct therapy in certain oncology protocols to manage chemotherapy-related side effects.

Dexona 0.5mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, specialty pharmacies, government health programs, and international pharmaceutical distributors.

DECMAX 4mg Tablet
Composition: Dexamethasone Tablets IP 4mg
International Trade Name: Decadron®

DECMAX 4 is a high-quality Dexamethasone 4mg Tablet, a bioequivalent formulation of the internationally recognized corticosteroid marketed under the brand name Decadron®. Manufactured in WHO-GMP certified facilities, DECMAX Tablets are supplied by trusted pharmaceutical exporters from India to support a wide range of therapeutic applications across oncology, neurology, immunology, and critical care.

Dexamethasone is a potent synthetic glucocorticoid with strong anti-inflammatory, anti-allergic, and immunosuppressive properties. DECMAX 4mg Tablets are widely used in the treatment of inflammatory and autoimmune disorders, cerebral edema, severe allergic reactions, adrenal insufficiency, and as an adjunct in cancer therapy, including management of brain tumor–associated edema and prevention of chemotherapy-induced nausea and hypersensitivity reactions.

DECMAX 4mg Tablets are manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade blister packaging (10 tablets) with complete regulatory documentation, making it suitable for hospitals, specialty clinics, oncology centers, government health programs, and international pharmaceutical distributors.

Temotero 250mg Capsule
Composition: Temozolomide Capsules 250mg IP
International Trade Name: Temodar®

Temotero 250 is a high-quality Temozolomide 250mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temotero Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temotero 250mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temotero 250mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Krabeva 400mg Injection
Composition: Bevacizumab 400mg/16mL (25mg/mL) Injection
International Trade Name: Avastin®

Krabeva 400 is a high-quality Bevacizumab 400mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Krabeva Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Krabeva 400mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Krabeva 400mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Bevatas 400mg Injection
Composition: Bevacizumab 400mg/16mL (25mg/mL) Injection
International Trade Name: Avastin®

Bevatas 400 is a high-quality Bevacizumab 400mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Bevatas Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Bevatas 400mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Bevatas 400mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Dexavac Tablet
Composition: Dexamethasone Tablets IP
International Trade Name: Decadron®

Dexavac is a high-quality Dexamethasone Tablet, a bioequivalent formulation of the internationally recognized corticosteroid marketed under the brand name Decadron®. Manufactured in WHO-GMP certified facilities, Dexavac Tablets are supplied by trusted pharmaceutical exporters from India to support a wide range of therapeutic applications across oncology, neurology, immunology, and general medicine.

Dexamethasone is a potent synthetic glucocorticoid with strong anti-inflammatory, anti-allergic, and immunosuppressive properties. Dexavac Tablets are commonly used in the management of inflammatory and autoimmune disorders, cerebral edema, severe allergic reactions, adrenal insufficiency, and as an adjunct therapy in cancer care, including management of brain tumor–associated edema and prevention of chemotherapy-induced nausea and hypersensitivity reactions.

Dexavac Dexamethasone Tablets are manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade blister packaging with complete regulatory documentation, making it suitable for hospitals, specialty clinics, oncology centers, government health programs, and international pharmaceutical distributors.

TAMOZYRA 100mg Capsule
Composition: Temozolomide Capsules 100mg IP
International Trade Name: Temodar®

TAMOZYRA 100 is a high-quality Temozolomide 100mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, TAMOZYRA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. TAMOZYRA 100mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

TAMOZYRA 100mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

TAMOZYRA 20mg Capsule
Composition: Temozolomide Capsules 20mg IP
International Trade Name: Temodar®

TAMOZYRA 20 is a high-quality Temozolomide 20mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, TAMOZYRA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. TAMOZYRA 20mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

TAMOZYRA 20mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

TAMOZYRA 250mg Capsule
Composition: Temozolomide Capsules 250mg IP
International Trade Name: Temodar®

TAMOZYRA 250 is a high-quality Temozolomide 250mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, TAMOZYRA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. TAMOZYRA 250mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

TAMOZYRA 250mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Evermil 5mg Tablet
Composition: Everolimus 5mg Tablets
International Trade Name: Certican®

Evermil 5 is a high-quality Everolimus 5mg Tablet, a bioequivalent formulation of the internationally recognized mTOR inhibitor marketed under the brand name Certican®. Manufactured in WHO-GMP certified facilities, Evermil Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and transplant treatment programs.

Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor that works by blocking the mTOR pathway, which is critical for cell growth, proliferation, and angiogenesis. Evermil 5mg Tablet is primarily indicated for the prevention of organ rejection in renal and liver transplant patients, as well as for treatment of certain cancers including advanced renal cell carcinoma, pancreatic neuroendocrine tumors, and breast cancer depending on approved treatment protocols.

Evermil 5mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology and transplant centers, specialty pharmacies, government health programs, and international pharmaceutical distributors.

Evermil 10mg Tablet
Composition: Everolimus 10mg Tablets
International Trade Name: Certican®

Evermil 10 is a high-quality Everolimus 10mg Tablet, a bioequivalent formulation of the internationally recognized mTOR inhibitor marketed under the brand name Certican®. Manufactured in WHO-GMP certified facilities, Evermil Tablets are supplied by trusted pharmaceutical exporters from India to support global oncology and transplant treatment programs.

Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor that works by blocking the mTOR pathway, which is critical for cell growth, proliferation, and angiogenesis. Evermil 10mg Tablet is primarily indicated for the prevention of organ rejection in renal and liver transplant patients, as well as for treatment of certain cancers including advanced renal cell carcinoma, pancreatic neuroendocrine tumors, and breast cancer, depending on approved treatment protocols.

Evermil 10mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, oncology and transplant centers, specialty pharmacies, government health programs, and international pharmaceutical distributors.

Everbliss 5mg Tablet
Composition: Everolimus 5mg Tablets
International Trade Name: Afinitor®

Everbliss 5 is a high-quality Everolimus 5mg Tablet, a bioequivalent formulation of the internationally recognized mTOR inhibitor marketed under the brand name Afinitor®. Manufactured in WHO-GMP certified facilities, Everbliss Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor that works by inhibiting the mTOR signaling pathway, thereby suppressing tumor cell proliferation, angiogenesis, and metabolic activity. Everbliss 5mg Tablet is primarily indicated for the treatment of advanced hormone receptor–positive, HER2-negative breast cancer, advanced renal cell carcinoma, pancreatic neuroendocrine tumors (PNET), subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex, and other approved oncology indications.

Everbliss 5mg Tablet is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, cancer specialty clinics, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

ALKEM DEXA 8mg Injection (2mL)
Composition: Dexamethasone Injection IP 4mg/mL (8mg/2mL)
International Trade Name: Decadron®

ALKEM DEXA 8mg is a high-quality Dexamethasone Injection, a bioequivalent formulation of the internationally recognized corticosteroid marketed under the brand name Decadron®. Manufactured by Alkem Laboratories in WHO-GMP certified facilities, this injection is widely supplied for hospital and institutional use in acute and chronic care settings.

Dexamethasone is a potent synthetic glucocorticoid with strong anti-inflammatory, anti-edema, anti-allergic, and immunosuppressive properties. ALKEM DEXA 8mg Injection is commonly indicated for the management of severe inflammatory and allergic conditions, cerebral edema, shock, adrenal insufficiency, and as an essential supportive therapy in oncology, including reduction of brain tumor–related edema and prevention of chemotherapy-induced nausea and hypersensitivity reactions.

ALKEM DEXA Dexamethasone Injection is manufactured under stringent GMP and injectable quality standards to ensure consistent potency, safety, and rapid therapeutic action. The product is supplied in sterile, hospital-grade ampoules/vials with secure, export-quality packaging and complete regulatory documentation, making it suitable for emergency care units, oncology infusion centers, ICUs, government hospitals, and international pharmaceutical distributors.

MESNYRA 400 Injection
Composition: Mensa (Mesna) 400mg/4mL Injection
International Trade Name: Mensa®

MESNYRA 400 is a high-quality Mesna 400mg Injection, a clinically proven uroprotective agent marketed under the brand name Mensa®. Manufactured in WHO-GMP certified facilities, MESNYRA Injection is supplied by trusted pharmaceutical exporters from India to support global oncology treatment programs, particularly in chemotherapy regimens involving cyclophosphamide or ifosfamide.

Mesna (2-mercaptoethanesulfonate sodium) works by binding to and detoxifying acrolein, a harmful metabolite of cyclophosphamide and ifosfamide, thereby preventing hemorrhagic cystitis and other urothelial toxicities. MESNYRA 400mg Injection is primarily indicated for prophylaxis of urotoxicity in patients receiving high-dose cyclophosphamide or ifosfamide, in accordance with established oncology protocols.

MESNYRA 400mg Injection is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent efficacy, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, chemotherapy centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Temotero 100mg Capsule
Composition: Temozolomide Capsules 100mg IP
International Trade Name: Temodar®

Temotero 100 is a high-quality Temozolomide 100mg Capsule, a bioequivalent formulation of the internationally recognized alkylating anticancer agent marketed under the brand name Temodar®. Manufactured in WHO-GMP certified facilities, Temotero Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in gliomas and other high-grade brain tumors.

Temozolomide is an oral alkylating agent that exerts cytotoxic effects by methylating DNA at the O6 and N7 positions of guanine, leading to tumor cell apoptosis. Temotero 100mg Capsule is primarily indicated for the treatment of adult patients with newly diagnosed glioblastoma in combination with radiotherapy, as well as relapsed or refractory anaplastic astrocytoma, and other high-grade gliomas according to approved treatment protocols.

Temotero 100mg Capsule is manufactured under stringent GMP and pharmaceutical quality standards to ensure consistent potency, safety, and therapeutic reliability. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for oncology hospitals, neuro-oncology centers, specialty pharmacies, government cancer programs, and international pharmaceutical distributors.

Abevmy 100mg Injection
Composition: Bevacizumab 100mg/4mL (25mg/mL) Injection
International Trade Name: Hertraz®

Abevmy 100 is a high-quality Bevacizumab 100mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Hertraz®. Manufactured in WHO-GMP certified biologics facilities, Abevmy Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Abevmy 100mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Abevmy 100mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Versavo 400mg Injection
Composition: Bevacizumab 400mg/16mL (25mg/mL) Injection
International Trade Name: Avastin®

Versavo 400 is a high-quality Bevacizumab 400mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Versavo Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Versavo 400mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Versavo 400mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Bevacirel 400 Injection
Composition: Bevacizumab 400mg/16mL (25mg/mL) Injection
International Trade Name: Avastin®

Bevacirel 400 is a high-quality Bevacizumab 400mg Injection, a biosimilar formulation of the internationally recognized VEGF-targeting monoclonal antibody marketed under the brand name Avastin®. Manufactured in WHO-GMP certified biologics facilities, Bevacirel Injection is supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors such as colorectal, lung, and renal cancers.

Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor blood vessel formation, thereby restricting tumor growth. Bevacirel 400mg Injection is primarily indicated for the treatment of metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, glioblastoma, and certain gynecologic malignancies, in combination with chemotherapy or as per approved protocols.

Bevacirel 400mg Injection is manufactured under stringent GMP and biologics quality standards to ensure consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.